Previous 10 | Next 10 |
Ultragenyx Pharmaceutical press release ( NASDAQ: RARE ): Q2 GAAP EPS of -$2.26 misses by $0.49 . Revenue of $89.34M (+2.7% Y/Y) beats by $2.01M . As of June 30, 2022, cash, cash equivalents, and marketable debt securities were $706.1 million Outlook: T...
Second quarter 2022 total revenue of $89.3 million and Crysvita® revenue in Ultragenyx territories 1 of $64.0 million Reaffirm 2022 Crysvita revenue in Ultragenyx territories guidance of $250 million to $260 million and Dojolvi revenue of $55 million to $65 millio...
Ultragenyx Pharmaceutical ( NASDAQ: RARE ) is scheduled to announce Q2 earnings results on Thursday, July 28th, after market close. The consensus EPS Estimate is -$1.64 and the consensus Revenue Estimate is $87.33M (+0.4% Y/Y). Over the last 3 months, EPS estimates hav...
NOVATO, Calif., July 25, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference ca...
With earnings season beginning to pick up steam, Wall Street experienced a buying spree on Tuesday. The Nasdaq led the broad-based advance, climbing 3% as the major averages bounced back from recent weakness. Amid the overall gains, Apellis ( APLS ) represented a standout performer....
Investors don't appear happy with Ultragenyx Pharmaceutical's ( NASDAQ: RARE ) closing bell announcement Monday that it would be acquiring GeneTx Biotherapeutics , which is solely focused on its Angelman syndrome drug GTX-102. Volume in Ultragenyx is much higher than n...
Gainers: Sidus Space ( SIDU ) +34% . DermTech ( DMTK ) +25% . Eos Energy Enterprises ( EOSE ) +24% . NuCana ( NCNA ) +21% . Power REIT ( PW ) +21% . Apellis Pharmaceuticals ( APLS ) +20% . Silvergate ( SI ) ...
Shares of the rare disease specialist Ultragenyx Pharmaceutical (NASDAQ: RARE) are having a rough session Tuesday. Specifically, the biotech's stock dropped by as much as 17% in early morning action. The company's shares have rebounded to some degree since, but Ultragenyx's ...
Gainers: Apellis Pharmaceuticals APLS +22% . Neuronetics STIM +17% . Nyxoah ( NYXH ) +17% . Celyad Oncology ( CYAD ) +8% . NuCana ( NCNA ) +7% . Losers: High Tide HITI -21% . Ultragenyx Pharmaceutical ( RARE ...
Ultragenyx Pharmaceutical ( NASDAQ: RARE ) on Monday said it had exercised its option to acquire GeneTx Biotherapeutics for a $75M upfront payment following promising interim data from a phase 1/2 study of the privately-held biotech company's investigational drug GTX-102. ...
News, Short Squeeze, Breakout and More Instantly...
Ultragenyx Pharmaceutical Inc. Company Name:
RARE Stock Symbol:
NASDAQ Market:
Ultragenyx Pharmaceutical Inc. Website:
NOVATO, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultrarare genetic diseases, today announced that it will host a conference call at 5...
NOVATO, Calif., July 24, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the company will share the latest clinical data, regulatory progress and program next steps for GTX-102, its investigational antisense oligonucleotide for Angelman syndrome, on Wed...
2024-07-24 04:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...